Product image of Metazero (Metoprolol Succinate) supplied by GNH India

Metazero

Active Ingredient:
Metoprolol Succinate
Origin:
EU

Metazero (Metoprolol Succinate)

Metoprolol succinate, the active ingredient in Metazero, is a beta blocker presented as an oral tablet for oral use. It is used to lower high blood pressure, relieve chest pain from chronic stable angina, improve outcomes in heart failure, and reduce the risk of further events after a myocardial infarction in adult patients.

GNH India supplies Metazero as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality and regulatory compliance.

Manufacturer / TM Owner

Krka, D.D., Novo Mesto

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

  • Metazero (metoprolol succinate) is employed in cardiovascular therapy to control blood pressure and reduce cardiac workload.
  • Hypertension: reduces systolic and diastolic pressure, decreasing risk of stroke and heart attack.
  • Chronic stable angina: decreases myocardial oxygen demand, relieving chest pain during exertion.
  • Heart failure: improves left ventricular function and reduces hospitalization rates.
  • Post‑myocardial infarction: lowers risk of recurrent infarction and improves survival.

How It Works

  • Metoprolol succinate selectively blocks β1‑adrenergic receptors in cardiac tissue, inhibiting the effects of endogenous catecholamines such as norepinephrine. This antagonism reduces heart rate, myocardial contractility, and conduction velocity, leading to decreased cardiac output and lower arterial pressure. By attenuating sympathetic stimulation, the drug also diminishes renin release from the kidneys, contributing further to blood pressure control.

Side Effects

Metazero may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects

  • Fatigue: feeling of tiredness or lack of energy.
  • Dizziness: light‑headed sensation, especially on standing.
  • Gastrointestinal upset: nausea, abdominal discomfort or constipation.

Serious or Rare Side Effects

  • Severe hypotension: markedly low blood pressure causing fainting.
  • Bradycardia: dangerously slow heart rate.
  • Bronchospasm: narrowing of airways, particularly in patients with asthma.

Precautions & Warnings

When prescribing Metazero, clinicians should consider several precautionary measures to ensure safe use.

  • Assess cardiovascular status: evaluate heart rate, blood pressure and conduction abnormalities before initiation.
  • Review concomitant medications: avoid use with other β‑blockers or drugs that may exacerbate bradycardia.
  • Monitor renal and hepatic function: dose adjustments may be needed in impairment.
  • Caution in asthma or COPD: β1‑selectivity may still affect bronchial tone.
  • Pregnancy and lactation: use only if potential benefit justifies potential risk, as safety data are limited.
  • Store at ambient temperature: keep below 25°C in the original packaging, protect from moisture.

Avoid Interactions

Metazero can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

  • Non‑selective β‑blockers: combined use can cause excessive bradycardia and hypotension.
  • Calcium channel blockers (verapamil, diltiazem): increase risk of heart block and severe hypotension.
  • Antidiabetic agents (insulin, sulfonylureas): may mask hypoglycemia symptoms.

Moderate Interactions (Monitor Closely)

  • Antidepressants (SSRIs, SNRIs): may enhance bradycardic effects.
  • NSAIDs (ibuprofen, naproxen): can reduce antihypertensive effect.
  • Digoxin: may increase plasma levels leading to toxicity.

Frequently Asked Questions

Metazero contains metoprolol succinate, a beta‑blocker indicated for the management of hypertension, chronic stable angina, heart failure, and secondary prevention after myocardial infarction. It works by lowering heart rate and blood pressure, thereby reducing cardiac workload and improving outcomes in these cardiovascular conditions.

Metoprolol succinate selectively antagonizes β1‑adrenergic receptors in the heart, blocking the action of norepinephrine and epinephrine. This reduces heart rate, myocardial contractility, and conduction velocity, leading to decreased cardiac output and lower arterial pressure, while also diminishing renin release from the kidneys.

The appropriate dose of Metazero is determined by the prescribing clinician based on the individual’s medical condition, response to therapy, and tolerability. Dosage may be initiated at a low level and titrated upward, with adjustments made for renal or hepatic impairment as needed.

Safety of metoprolol succinate in pregnancy and lactation has not been fully established. It should be used only if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision should be made in consultation with a healthcare professional.

To request Metazero, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Metazero (metoprolol succinate) is a long‑acting, β1‑selective blocker, offering once‑daily dosing and steady plasma concentrations. Compared with non‑selective agents like propranolol, it has a lower risk of bronchospasm, and its extended‑release formulation may improve adherence relative to short‑acting beta‑blockers.

Metazero should be stored at ambient temperature, preferably below 25 °C, in its original container to protect it from moisture and light. Keep the product out of reach of children and avoid storing in humid or excessively hot environments.

Metazero is taken orally, usually once daily, with or without food as directed by the prescriber. Tablets should be swallowed whole with a glass of water and not chewed or crushed unless specifically instructed.

The most serious adverse events include severe hypotension, marked bradycardia, heart block, and bronchospasm, especially in patients with underlying respiratory disease. Prompt medical attention is required if symptoms such as fainting, extreme fatigue, difficulty breathing, or irregular heartbeats occur.

Metazero is contraindicated in patients with known hypersensitivity to metoprolol or any component of the formulation, those with severe bradycardia, second‑ or third‑degree heart block without a pacemaker, and individuals in cardiogenic shock. Caution is also advised for patients with uncontrolled asthma or severe peripheral vascular disease.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Metoprolol Succinate

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT